Lilly and Millenium cut the genome cake a new way

摘要

ALLENTOWN, PA--Pharmaceutical companies have pledged nearly 400 million dollar to the leading genomics firms during the past six months. The latest deal involves Millennium Pharmaceuticals (Cambridge, MA) and Eli Lilly (Indianapolis, IN) in atherosclerosis, an alliance that includes upf ront equity and licensing payments and guaranteed research funding worth nearly 45 million dollar, R&D milestone payments and royalties could boost its value even further.